Booster backs ventilator startup RespirAq in $138K seed deal
What's the deal? Booster Innovation Fund has invested US$161.8K in RespirAqDealroom has a profile for this one. Try Dealroom →, a seed-stage New Zealand company developing a water-free respiratory humidification platform for hospital ventilators.
What's the endgame? RespirAq, spun out of Auckland University of Technology in 2022, uses a proprietary smart material to capture moisture from exhaled breath and return it during inhalation. That replaces conventional heated water humidifiers, which need regular refilling and create condensation in air-supply tubes. The company says its first product aims to match clinical outcomes while simplifying hospital workflow.
Why Booster? The fund invests in early-stage companies built on intellectual property developed in New Zealand. RespirAq now represents 0.9% of its portfolio, which spans more than 40 active companies and carries a net asset value of US$18.3M.
The bigger picture: This is a modest follow-on rather than a major new financing. RespirAq has previously raised US$970.6K from Outset VenturesDealroom has a profile for this one. Try Dealroom →, Icehouse VenturesDealroom has a profile for this one. Try Dealroom →, and Cure Kids VenturesDealroom has a profile for this one. Try Dealroom →, followed by a US$1.94M round led by Movac's Emerge Fund 4Dealroom has a profile for this one. Try Dealroom → in 2024 to expand manufacturing.
What could go wrong? RespirAq's technology received FDA Breakthrough Device designation in 2023, but that is not marketing approval. The company remains in the regulatory process as it moves toward commercialization.
The signal: The round reflects continued local backing for a homegrown medtech startup as it shifts from development toward market, with Booster framing the deal as support for New Zealand businesses "at the seed of their growth."
Read more: kalkine.co.nz
Image credit: "Ventilator control panel" by quinn.anya, licensed under CC BY-SA 2.0